Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvelestat in Alpha-1 Antitrypsin Deficiency (Mechanistic Phase 2 Study)
2018-001309-95Phase 2Unknown
- Sponsor
- Mereo BioPharma
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alpha-1 antitrypsin deficiency (AATD) comparing Alvelestat BID with Placebo BID (2 arms). Primary endpoint: Within-individual percent change from baseline in plasma desmosine/isodesmosine. Status: unknown.
02
Drugs
alvelestat
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on 2018-001309-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001309-95.